Persistent Asset Partners’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$43K Buy
3,466
+2,572
+288% +$89.1K 0.01% 469
2026
Q2
$114K Buy
+894
New +$28.9K 0.03% 273
2026
Q1
– Sell
-851
Closed -$52.5K – 480
2025
Q4
$52.5K Buy
+851
New +$30.2K 0.02% 292

Other funds holding VKTX

Persistent Asset Partners's VKTX Position: Q3 2026 in Review

Persistent Asset Partners reduced its Viking Therapeutics (VKTX) stake by 1% in Q3 2026, selling an estimated $39.4K and leaving 111,598 shares worth $3.64M. The position accounts for 1% of the portfolio, ranked #20.

Persistent Asset Partners first reported a position in VKTX in Q1 2025 and has held it in 7 quarters since. The position peaked at $4.4M in Q2 2026. 444 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Persistent Asset Partners held 111,598 shares of Viking Therapeutics worth $3.64M as of Q3 2026.
  • Persistent Asset Partners sold 1,138 Viking Therapeutics shares in Q3 2026, an estimated $39.4K.
  • Viking Therapeutics made up 1% of Persistent Asset Partners's portfolio in Q3 2026, its #20 holding.
  • Persistent Asset Partners first reported a position in Viking Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Persistent Asset Partners's Viking Therapeutics position peaked at $4.4M in Q2 2026.
  • 444 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.